KR20190117014A - 방광암의 항-pd-l1 항체 치료 - Google Patents

방광암의 항-pd-l1 항체 치료 Download PDF

Info

Publication number
KR20190117014A
KR20190117014A KR1020197026803A KR20197026803A KR20190117014A KR 20190117014 A KR20190117014 A KR 20190117014A KR 1020197026803 A KR1020197026803 A KR 1020197026803A KR 20197026803 A KR20197026803 A KR 20197026803A KR 20190117014 A KR20190117014 A KR 20190117014A
Authority
KR
South Korea
Prior art keywords
subject
bladder cancer
binding fragment
antibody
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197026803A
Other languages
English (en)
Korean (ko)
Inventor
죤 쿨랜드
로버트 이안논
리 시
모하메드 다르
영 벤
죤 앤드류 블레이크-하스킨즈
마그달레나 자작
마를론 레벨라토
아쇼크 굽타
토니 호
질 워커
크시아오핑 진
샤논 모리스
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Priority to KR1020237034594A priority Critical patent/KR20230145547A/ko
Publication of KR20190117014A publication Critical patent/KR20190117014A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197026803A 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료 Ceased KR20190117014A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034594A KR20230145547A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459,700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034594A Division KR20230145547A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Publications (1)

Publication Number Publication Date
KR20190117014A true KR20190117014A (ko) 2019-10-15

Family

ID=63169615

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197026803A Ceased KR20190117014A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020257004753A Pending KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020237034594A Ceased KR20230145547A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257004753A Pending KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020237034594A Ceased KR20230145547A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Country Status (12)

Country Link
US (2) US20190359715A1 (https=)
EP (1) EP3582805A4 (https=)
JP (2) JP2020507596A (https=)
KR (3) KR20190117014A (https=)
CN (2) CN110290803A (https=)
AU (2) AU2018221822A1 (https=)
CA (1) CA3052652A1 (https=)
EA (1) EA201991870A1 (https=)
IL (3) IL302777A (https=)
MA (1) MA47509A (https=)
SG (1) SG11201907211TA (https=)
WO (1) WO2018152415A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3142751T (pt) * 2014-05-13 2019-10-25 Medimmune Ltd Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
SG11201907211TA (en) * 2017-02-16 2019-09-27 Medimmune Llc Anti-pd-l1 antibody treatment of bladder cancer
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP4153783A1 (en) * 2020-05-21 2023-03-29 Astrazeneca AB Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
US20250388678A1 (en) * 2024-06-25 2025-12-25 Astrazeneca Ab Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT3142751T (pt) * 2014-05-13 2019-10-25 Medimmune Ltd Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP7144935B2 (ja) * 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
SG11201907211TA (en) * 2017-02-16 2019-09-27 Medimmune Llc Anti-pd-l1 antibody treatment of bladder cancer

Also Published As

Publication number Publication date
EP3582805A4 (en) 2021-03-10
WO2018152415A1 (en) 2018-08-23
EP3582805A1 (en) 2019-12-25
SG11201907211TA (en) 2019-09-27
IL320916A (en) 2025-07-01
AU2025201227A1 (en) 2025-03-13
IL268460A (en) 2019-09-26
AU2018221822A1 (en) 2019-09-26
US20220332828A1 (en) 2022-10-20
KR20230145547A (ko) 2023-10-17
CN110290803A (zh) 2019-09-27
CN118001389A (zh) 2024-05-10
US20190359715A1 (en) 2019-11-28
IL302777A (en) 2023-07-01
CA3052652A1 (en) 2018-08-23
JP2024038034A (ja) 2024-03-19
KR20250025517A (ko) 2025-02-21
JP2020507596A (ja) 2020-03-12
MA47509A (fr) 2019-12-25
EA201991870A1 (ru) 2020-02-12

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
WO2014194293A1 (en) Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
JP2021510697A (ja) がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
US20260109766A1 (en) Lag-3 antagonist therapy for melanoma
US20250340645A1 (en) Methods of treating tumor
JP7809635B2 (ja) Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
US20230265188A1 (en) Lag-3 antagonist therapy for hepatocellular carcinoma
KR20240153583A (ko) 결장직장암종에 대한 병용 요법
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
WO2021160152A1 (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
WO2024196952A1 (en) Tumor subtype assessment for cancer therapy
KR20250123912A (ko) 폐암에 대한 병용 요법
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
WO2026052650A1 (en) Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230410

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231010

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I